NTHI
Neonc Technologies Holdings, Inc. NASDAQ Listed Mar 26, 2025$4.88
-4.50%
vs $5.11
Mkt Cap $93.8M
52w Low $3.35
17.5% of range
52w High $12.09
50d MA $4.96
200d MA $8.13
P/E (TTM)
-2.5x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.4x
ROE
355.0%
P/FCF
-4.5x
RSI (14)
54.50
ATR (14)
$0.57
Beta
3.60
50d MA
$4.96
200d MA
$8.13
Avg Volume
96.9K
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
8335 Sunset Boulevard · Calabasas, CA 90069 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | AMC | -0.22 | -0.38 | -73.5% | 5.34 | -1.5% | +2.6% | -1.1% | -1.1% | -0.4% | -3.7% | — |
| Mar 31, 2026 | AMC | -0.37 | -0.46 | -25.4% | 7.01 | -0.1% | -13.1% | -2.3% | -3.5% | +1.4% | -7.7% | — |
| Nov 14, 2025 | AMC | -0.37 | -0.45 | -21.6% | 9.08 | +0.2% | -12.3% | -11.3% | -4.7% | -11.9% | -1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Alliance Global Partners | Initiates | Buy | $13 | $5.34 | $5.26 | -1.5% | +2.6% | -1.1% | -1.1% | -0.4% | -3.7% |
| May 18 | Maxim Group | Initiates | Buy | $20 | $5.50 | $5.59 | +1.6% | -2.9% | +2.6% | -1.1% | -1.1% | -0.4% |
| Apr 24 | BTIG Research | Initiates | Buy | $15 | $4.79 | $5.30 | +10.6% | -0.2% | -3.6% | -6.5% | -0.2% | +2.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Heshmatpour Amir F | President | Buy | 10,000 | $4.16 | $42K | 3,072,000 | +20.53% | +0.92% |
| Apr 28, 2026 | Heshmatpour Amir F | President | Buy | 10,000 | $4.52 | $45K | 3,062,000 | -0.23% | +20.91% |
8-K · 7.01
! Medium
Neonc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 23
8-K · 7.01
! Medium
Neonc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies Holdings disclosed material non-public information on June 16, 2026, via press release, subject to Regulation FD requirements for fair disclosure to investors.
Jun 18
8-K · 1.01
!! High
Neonc Technologies Holdings, Inc. -- 8-K 1.01: Material Agreement
Jun 12
8-K · 1.01
!! High
NeOnc Technologies Holdings, Inc. -- 8-K 1.01: Material Agreement
NeOnc Technologies Holdings (NTHI) secured $10 million in funding through a Securities Purchase Agreement, providing capital for operations and growth initiatives.
Apr 24
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
NeOnc disclosed material non-public information via Regulation FD, potentially signaling upcoming announcements about clinical progress or business developments that could significantly impact the biotech stock's valuation.
Apr 16
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
NTHI entered a material agreement with BTIG (a major investment bank), likely signaling capital raising, merger advisory, or strategic transaction discussions that could substantially alter the company's financial position or ownership structure.
Apr 10
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies disclosed material information via press release on April 1, 2026, which investors should review directly as it may impact stock valuation and trading decisions.
Apr 3
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
NTHI entered a material agreement that could significantly impact financial performance and investor returns, warranting immediate review of the full filing details to assess strategic implications.
Mar 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
NTHI's executive change involves new employment and equity compensation terms detailed in filed agreements, signaling potential leadership transition that could impact strategy and shareholder value depending on the executive's role and responsibilities.
Mar 17
8-K · 7.01
! Medium
NeOnc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies Holdings disclosed material information via press release on March 4, 2026, requiring investors to review Exhibit 99.1 for specific details about the company announcement.
Mar 6
8-K · 8.01
!! High
NeOnc Technologies Holdings, Inc. -- 8-K 8.01: Material Event / Announcement
NeOnc Technologies granted Fox Infused an intellectual property license and supply agreement for certain patented products, establishing a new revenue-generating partnership effective July 2022.
Mar 4
8-K · 1.01
!! High
NeOnc Technologies Holdings, Inc. -- 8-K 1.01: Material Agreement
NeOnc Technologies Holdings signed a $10 million securities purchase agreement, providing capital for operations and potential growth initiatives.
Mar 3
8-K · 7.01
! Medium
NeOnc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies will present early Phase 1 data from its NEO212-01 clinical trial on February 27, 2026, potentially demonstrating safety and dosing information for investors evaluating the company's development progress.
Feb 27
Institutional (13F) — Top 15
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bank Of America Corp /de/ | 235,396 | $2M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 215,700 | $2M | New | Mar 2026 |
| 3 | Millennium Management | 119,249 | $836K | New | Mar 2026 |
| 4 | Susquehanna International Group, Llp | 91,036 | $638K | New | Mar 2026 |
| 5 | Westmount Partners, Llc | 43,320 | $304K | — | Mar 2026 |
| 6 | Northern Trust Corp | 23,271 | $163K | — | Mar 2026 |
| 7 | Morgan Stanley | 16,408 | $136K | New | Dec 2025 |
| 8 | Hcr Wealth Advisors | 15,000 | $124K | — | Dec 2025 |
| 9 | Royal Bank Of Canada | 16,625 | $117K | — | Mar 2026 |
| 10 | Marshall Wace, Llp | 12,578 | $88K | New | Mar 2026 |
| 11 | Hrt Financial Lp | 11,432 | $80K | New | Mar 2026 |
| 12 | Barclays Plc | 8,062 | $57K | Reduced | Mar 2026 |
| 13 | Wells Fargo & Company/mn | 1,500 | $11K | New | Mar 2026 |
| 14 | Citigroup Inc | 613 | $5K | New | Dec 2025 |
| 15 | Ubs Group Ag | 273 | $2K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 52,201 | $533K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 20,677 | $211K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 15,729 | $161K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 12,122 | $124K | Feb 2026 |
| 5 | iShares Micro-Cap ETF | 12,845 | $90K | Mar 2026 |
| 6 | Ultra-Small Company Market Fund | 7,100 | $50K | Mar 2026 |
Valuation
Market Cap
$93.8M
Enterprise Value
$93.7M
P/E (TTM)
-2.52x
Forward P/E
—
PEG Ratio
0.00x
P/B
—
P/S
—
P/FCF
-4.49x
EV/EBITDA
—
Shares Out
19.2M
Financials (TTM)
Revenue
$0
Net Income
-$38.6M
EBITDA
-$35.2M
Free Cash Flow
-$20.9M
Op Cash Flow
-$20.4M
EPS Basic
$-3.23
EPS Diluted
$-1.94
EPS Forward
$-0.86
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$2.8M
Total Liab.
$20.3M
Total Equity
-$17.5M
Cash
$59K
LT Debt
$0
Book Value/Sh
$-0.91
Debt/Equity
-0.36x
Current Ratio
0.07
Quick Ratio
0.07
Returns & Growth
ROE
355.0%
ROA
-2200.9%
ROIC
519.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
—
Price Returns
2W
-15.0%
1M
+5.0%
3M
-54.6%
6M
-48.2%
12M
-35.9%
Technicals
52W High
$12.09
52W Low
$3.35
50d MA
$4.96
200d MA
$8.13
RSI (14)
54.50
ATR (14)
$0.57
Beta
3.60
Avg Volume
97K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.00
High
$15.00
Low
$15.00
Median
$15.00
Data updated apr 26, 2026 3:57pm
· Source: financialmodelingprep.com